Laura Martincich MD, Presenter: Consultant, General Electric Company Speaker, Bracco Group

Mathieu Faivre-Pierret MD, Abstract Co-Author: Nothing to Disclose

Christian Zechmann MD, Abstract Co-Author: Consultant, Bracco Group

Stefano Corcione MD, Abstract Co-Author: Nothing to Disclose

Federica Pediconi MD, Abstract Co-Author: Nothing to Disclose

Fiona Jane Gilbert MD, Abstract Co-Author: Nothing to Disclose

Harrie Cornelis M. Van Den Bosch MD, Abstract Co-Author: Nothing to Disclose

Francesco Sardanelli MD, Abstract Co-Author: Consultant, Bracco Group Research grant, Bracco Group Consultant, Bayer AG Research grant, Bayer AG

To intra-individually compare gadobenate dimeglumine (MultiHance)-enhanced MRI with gadopentetate dimeglumine (Magnevist)-enhanced MRI, mammography and ultrasound using a prospective, multi-center double-blinded, randomized protocol.

One hundred thirty-five women (52.25±12.61 years) with BIRADS 3/4/5 findings on mammography and/or ultrasound underwent two identical breast MRI exams in randomized order, one with gadobenate dimeglumine and the other with gadopentetate dimeglumine each at a dose of 0.1 mmol/kg BW. Of these patients, 88 underwent mammography and ultrasound, 21 only mammography and 26 only ultrasound. MRI was performed at 1.5T using T2w and 3D spoiled T1w GRE sequences with a temporal resolution of ≤2 min. Images were evaluated independently by three, unaffiliated, blinded radiologists for cancer detection. Imaging findings were matched with histology data by a fourth independent, blinded, radiologist. Malignant lesion detection rates were compared (McNemar’s test).

122 malignant lesions were confirmed at histology in 109 patients undergoing MRI and mammography while 123 were confirmed in 114 patients undergoing MRI and ultrasound. Significant superiority for gadobenate dimeglumine over gadopentetate dimeglumine was noted by each reader for cancer nodule detection (115-117 [94-96%] vs. 99-104 [81-85%] lesions detected; p<0.001). Significantly greater cancer detection was noted by all readers for gadobenate dimeglumine-enhanced MRI versus mammography (115-117 [94-96%] vs. 95 [78%] lesions detected; p<0.001) and ultrasound (112-116 [91-94%] vs. 89 [72%] lesions detected; p<0.001). Conversely, significantly greater cancer detection with gadopentetate dimeglumine-enhanced MRI was noted by just one reader in the comparison with ultrasound (101 [82%] vs. 89 [72%] lesions detected; p=0.046). No safety concerns were noted.

Significantly improved breast cancer detection is achievable on MRI enhanced with 0.1 mmol/kg BW gadobenate dimeglumine than on mammography, ultrasound or MRI enhanced with 0.1 mmol/kg BW gadopentetate dimeglumine.

MRI enhanced with gadobenate dimeglumine may prove advantageous compared to ultrasound, conventional mammography and MRI enhanced with gadopentetate dimeglumine for breast cancer screening.

Martincich, L, Faivre-Pierret, M, Zechmann, C, Corcione, S, Pediconi, F, Gilbert, F, Van Den Bosch, H, Sardanelli, F, Intra-individual Comparison of Gadobenate Dimeglumine-enhanced Breast MRI with Gadopentetate Dimeglumine-enhanced MRI, Conventional Mammography, and Ultrasound for Breast Cancer Detection.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11005970.html